Data Show Lebrikizumab Atopic Dermatitis Effects Maintained ...Middle East

Medscape - News
Lebrikizumab shows good long-term efficacy and reasonable safety in patients with moderate to severe atopic dermatitis according to the 52-week results from the phase 3 ADvocate1 and ADvocate2 trials. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Data Show Lebrikizumab Atopic Dermatitis Effects Maintained )

Also on site :